Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.~* Been treated for early breast cancer with standard of care duration of trastuzumab.~* Could have been treated neoadjuvantly but have not reached pathologic complete response.~Exclusion Criteria:~* Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.~* History of heart disease.~* Corrected QT (QTc) interval \>0.45 seconds~* History of gastrointestinal disease with diarrhea as the major symptom.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neratinib (Type: EXPERIMENTAL): 240 mg orally daily for one year
- Placebo (Type: PLACEBO_COMPARATOR): orally daily for one year

Based on this trial design, predict the completion outcome and termination type (if applicable).